

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

**COMPLETION OF THE PROPOSED DISPOSAL OF THE REMAINING 12% EQUITY INTEREST IN
TIANJIN TSKF PHARMACEUTICAL CO., LTD. (中美天津史克制药有限公司) TO HALEON CHINA
CO., LTD. AND HALEON CH SARL**

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. INTRODUCTION

The Board refers to:

- (a) the announcement dated 15 April 2025 made by the Company in relation to the resolutions passed at the 2nd Board meeting for the financial year ending 31 December 2025;
- (b) the announcement dated 15 April 2025 made by the Company in relation to the proposed disposal of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司) (the “**Target Company**”) to Haleon China Co., Ltd. and Haleon CH SARL (the “**Proposed DRT Disposal**”), and entry into an equity transfer agreement in relation thereto;
- (c) the circular dated 23 May 2025 (the “**Circular**”) to the shareholders of the Company in relation to the Proposed DRT Disposal; and
- (d) the announcement dated 9 June 2025 made by the Company in relation to the poll results of the extraordinary general meeting of the Company held on 9 June 2025.

Unless otherwise defined, all capitalised terms used and not defined herein shall have the same meanings ascribed to them in the Circular.

2. COMPLETION OF THE PROPOSED DRT DISPOSAL

The Board wishes to announce that the Company has received the Transfer Price (being an aggregate of RMB1,623,466,666.67) from the Transferees, and that the relevant industrial and commercial registration procedures in respect of the Proposed DRT Disposal have been completed.

Accordingly, completion of the Proposed DRT Disposal has taken place today, following which the Company has ceased to hold any equity interest in the Target Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
27 June 2025